Forging a position as an innovative player in
infectious disease vaccines and therapies

About Our Disease Targets

We use our in-house expertise in development of therapeutics and in infectious disease plus our extensive partnership network to identify the best cost-effective commercial opportunities for portfolio value growth.

The focus on infectious diseases is timely. The worldwide anti-infectives market is projected to reach an astounding US$111 billion by 2024. Anti-infectives include antivirals, antifungals and antibacterials .

BioDiem’s development work currently focuses on the following key disease targets:

  • Influenza
  • Antibiotic-resistant infections
  • Sexually transmitted infections (STIs)
  • Serious bacterial infections
  • Invasive fungal infections